Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)
2020; Lippincott Williams & Wilkins; Volume: 39; Issue: 4 Linguagem: Inglês
10.1200/jco.20.01994
ISSN1527-7755
AutoresScott Kopetz, Katherine A. Guthrie, Van K. Morris, Heinz‐Josef Lenz, Anthony M. Magliocco, Dipen M. Maru, Yibing Yan, Richard B. Lanman, Ganiraju C. Manyam, David S. Hong, Alexey V. Sorokin, Chloé E. Atreya, Luis A. Díaz, Carmen J. Allegra, Kanwal Raghav, Stephen E Wang, Christopher H. Lieu, Shannon McDonough, Philip A. Philip, Howard S. Höchster,
Tópico(s)Melanoma and MAPK Pathways
Resumomutations are rarely associated with objective responses to the BRAF inhibitor vemurafenib in patients with metastatic colorectal cancer (CRC). Blockade of
Referência(s)